Likelihood of False-Positive Chlamydia Test
The likelihood of a false-positive chlamydia test using modern NAATs is highly dependent on the prevalence of infection in the population being tested—in low-prevalence populations (<5%), up to 56% of positive results may be false positives, while in high-prevalence populations (≥15%), only about 12% of positive results are false positives.
Understanding the Problem: Specificity vs. Predictive Value
Modern NAATs have excellent specificity (97-99%) 1, but this does not mean false positives are rare. The critical concept here is positive predictive value (PPV)—the proportion of positive test results that are truly positive—which depends on both test specificity AND disease prevalence in your patient population.
The Mathematics of False Positives
Using a NAAT with 98% specificity and 80% sensitivity 1:
High-prevalence population (15% chlamydia prevalence):
- Out of 1,000 patients tested: 137 test positive
- 120 are true positives, 17 are false positives
- PPV = 88% (meaning 12% of positives are false) 1
Low-prevalence population (2% chlamydia prevalence):
- Out of 1,000 patients tested: 36 test positive
- 16 are true positives, 20 are false positives
- PPV = 44% (meaning 56% of positives are false) 1
At 5% prevalence threshold:
- PPV drops to 80%, meaning 20% of positive results are false positives 1
Clinical Algorithm for Managing Positive Results
Step 1: Assess Patient Risk Profile
Low-risk indicators (consider confirmatory testing):
- Monogamous relationship
- No history of STDs
- Population prevalence <5%
- Significant psychosocial consequences of false diagnosis 1
High-risk indicators (treat immediately):
- Multiple partners
- Partner with known STD
- Population prevalence ≥15%
- Symptomatic presentation
Step 2: Confirmatory Testing Strategy
For low-risk patients with positive screening results, verify using 1:
Best option: Second NAAT targeting a different nucleic acid sequence than the screening test
- Use the original specimen if available
- High concordance between different NAAT platforms (97.3% agreement) 2
Alternative: Culture with fluorescein-conjugated C. trachomatis-specific antibody
- Most specific method
- Reserve for medicolegal situations
- Requires second specimen collection
Blocking antibody test (for EIA tests only)
- Does not require second specimen
- Adequate performance demonstrated 1
Step 3: Treatment Decision
Treat immediately while awaiting confirmation if:
- Patient unlikely to return for follow-up
- Risk of transmission outweighs risk of false diagnosis
- Partner notification already initiated
Defer treatment pending confirmation if:
- Low-risk patient in monogamous relationship
- Significant adverse psychosocial consequences likely
- Patient reliable for follow-up
- No symptoms present
Critical Pitfalls to Avoid
Environmental Contamination Risk
CT ribosomal RNA can persist in clinical environments for at least 50 days and contaminate specimens 3. This is particularly problematic in:
- Non-clinical screening settings
- High-volume testing facilities
- Shared specimen collection areas
Point-of-Care Tests Are Inadequate
Commercial POC tests have unacceptably low sensitivities (12-82.6%) in women and should not be used for screening 4. Only validated NAATs are recommended 5, 6.
Specimen Type Matters
- Modern NAATs perform well on self-collected vaginal swabs and urine
- Confirmatory testing should use the same specimen type when possible
- Culture requires urethral/cervical swabs, not urine
Quality Control Considerations
Even in proficiency testing among 96 laboratories, only 72.5% reported completely correct results on standardized panels, with sensitivity problems occurring frequently 7. This underscores that false results can occur even with proper technique.
The bottom line: In asymptomatic patients from low-prevalence populations, always consider confirmatory testing before initiating partner notification or treatment that could have significant psychosocial consequences. The risk of false-positive diagnosis is real and substantial in these settings 1.